REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug targets Hard-to-Treat lymphoma in early trial
Disease control OngoingThis early-phase trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have returned or not improved after standard treatments. The drug is a monoclonal antibody designed to help the immune system fight cancer. The main goals are to find the …
Matched conditions: REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New drug combo targets tough lymphoma cases
Disease control TerminatedThis study tests a combination of two drugs, epcoritamab and tazemetostat, in people with a type of blood cancer called follicular lymphoma that has come back or not responded to prior treatments. The goal is to see if the combination is safe and effective at shrinking or elimina…
Matched conditions: REFRACTORY GRADE 2 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 19, 2026 12:01 UTC